Melatonin and breast cancer: Evidences from preclinical and human studies

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16370%2F18%3A43877056" target="_blank" >RIV/62157124:16370/18:43877056 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.1016/j.critrcvonc.2017.12.018" target="_blank" >http://dx.doi.org/10.1016/j.critrcvonc.2017.12.018</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.critrcvonc.2017.12.018" target="_blank" >10.1016/j.critrcvonc.2017.12.018</a>

Result language

angličtina

Original language name

Melatonin and breast cancer: Evidences from preclinical and human studies

Original language description

The breast cancer affects women with high mortality and morbidity worldwide. The risk is highest in the most developed world but also is markedly rising in the developing countries. It is well documented that melatonin has a significant anti-tumor activities demonstrated on various cancer types in a plethora of preclinical studies. In breast cancer, melatonin is capable to disrupt estrogen-dependent cell signaling, resulting in a reduction of estrogen-stimulated cells, moreover, it&apos;s obvious neuro-immunomodulatory effect in organism was described. Several prospective studies have demonstrated the inverse correlation between melatonin metabolites and the risk of breast cancer. This correlation was confirmed by observational studies that found lower melatonin levels in breast cancer patients. Moreover, clinical studies have showed that circadian disruption of melatonin synthesis, specifically night shift work, is linked to increased breast cancer risk. In this regard, proper light/dark exposure with more selective use of light at night along with oral supplementation of melatonin may have benefits for high-risk women. The results of current preclinical studies, the mechanism of action, and clinical efficacy of melatonin in breast cancer are reviewed in this paper. Melatonin alone or in combined administration seems to be appropriate drug for the treatment of early stages of breast cancer with documented low toxicity over a wide range of doses. These and other issues are also discussed.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30107 - Medicinal chemistry

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Critical reviews in oncology hematology

ISSN

1040-8428

e-ISSN

—

Volume of the periodical

122

Issue of the periodical within the volume

February

Country of publishing house

US - UNITED STATES

Number of pages

11

Pages from-to

133-143

UT code for WoS article

000427315100013

EID of the result in the Scopus database

2-s2.0-85042742947